Compare Invesco NASDAQ 100 ETF (QQQM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs TG Therapeutics Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $294.52, while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). Which is the better fit depends on your goals.
| QQQM | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $59.06 |
52-Week Low | $229.87 | $26.94 |
Market Cap | — | $8.53B |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $295.76, down 0.1% with a bullish technical signal from moving averages. The ETF tracks the Nasdaq-100 index, offering diversified exposure to large-cap growth stocks. Recent news highlights QQQM's low expense ratio advantage over QQQ and its position as a core growth allocation option for investors seeking Nasdaq-100 exposure.
The outlook remains positive for long-term growth investors, with technical indicators supporting bullish momentum. Key risks include concentration in top holdings and market sensitivity to technology sector performance. The ETF's low-cost structure provides a competitive advantage for sustained investment.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
